12:00 AM
 | 
Jul 02, 2012
 |  BC Week In Review  |  Company News  |  Deals

AmDerma, Oculus deal

Oculus granted AmDerma exclusive rights to develop and commercialize compounds using Oculus' Microcyn technology for dermatology indications, including acne. AmDerma will have rights to...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >